Breaking News, Collaborations & Alliances

Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio

Strengthens Cullinan’s portfolio of autoimmune programs with the opportunity to address a broader range of diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Cullinan Therapeutics Inc., a biopharmaceutical company focused on developing modality-agnostic targeted therapies, has entered into an agreement with Genrix Bio for a global (ex-Greater China), all indication, exclusive license to velinotamig, a BCMAxCD3 bispecific T cell engager. Velinotamig has demonstrated potential best-in-class efficacy at the Phase 2 target dose in nearly 50 patients with relapsed/refractory (r/r) multiple myeloma (MM). Cullinan will develop velinotamig in autoimmune d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters